Tests AZD6750 alone and with other drugs in advanced solid tumors
Tests AZD6750, an IL-2 treatment, in adults with advanced solid cancers.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Key facts
- Where
- Seoul, South KoreaSee the site
- Phase
- Phase 1/2
Where in South Korea
- SeoulSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07115043
- Record updated
- 8 October 2026
- Original description
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRead full original descriptionShow less
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Inclusion: Participant ≥ 18 year; ECOG PS of 0 to 1; Provision of 'archival' tumor specimen; At least one measurable lesion according to RECIST v1.1,; Minimum life expectancy of 12 weeks; Adequate and stable cardiac function; Adequate bone marrow, liver and kidney function; Body weight ≥ 35 kg; Capable of giving signed informed consent; Module 1 specific inclusion criteria:; Participants with locally advanced or metastatic select solid tumors (MM, Squamous cell carcinoma of skin, MCC, NSCLC, Head and neck squamous cell carcinoma, Gastric cancer/gastroesophaegeal junction cancer, RCC, HGSOC, Triple negative breast cancer) who have received adequate SoC; Module 2 specific inclusion criteria:; Participants with Stage IV NSCLC Dose Escalation/Backfills; Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR; Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%; Dose Expansion; <!-- -->; Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.
Exclusion: History or planned organ or allogeneic stem cell transplantation; Active or prior documented autoimmune or inflammatory disorders, within the past 3 years; Any prior toxicities that led to permanent discontinuation of prior immunotherapy; Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy; Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids; Prior history of Grade ≥ 3 non-infectious pneumonitis; Participant requires chronic immunosuppressive therapy (including steroids > 10 mg prednisone/day or equivalent); Receipt of live attenuated vaccine within 30 days; Module 2 specific exclusion criteria:; Previous treatment with anti-TIGIT therapy; Any evidence of:; Severe or uncontrolled systemic diseases including respiratory, cardiac or tumor-related conditions; Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis; Active uncontrolled or chronic infection of hepatitis B, hepatitis C; 1L NSCLC participants with genetic alteration such as EGFR that has a targeted therapy in 1L as per local SoC.